贝伐-话题@MedSci

#贝伐#

228篇内容 | 4142人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1476912, encodeId=894d14e69126e, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=NEJM：新辅助化疗和贝伐单抗治疗HER2-阴性乳腺癌, objectType=article, longId=3843, objectId=f46038438c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f46038438c, replyNumber=0, likeNumber=73, createdTime=2012-02-05, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f46038438c, moduleTitle=NEJM：新辅助化疗和贝伐单抗治疗HER2-阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f46038438c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476911, encodeId=4b7614e6911c0, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=NEJM：新辅助化疗加贝伐单抗治疗乳腺癌, objectType=article, longId=3842, objectId=9f1b38428d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f1b38428d, replyNumber=0, likeNumber=77, createdTime=2012-02-05, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f1b38428d, moduleTitle=NEJM：新辅助化疗加贝伐单抗治疗乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f1b38428d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476910, encodeId=b4e014e6910c3, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=NEJM：贝伐单抗提高攻击性乳腺癌患者生存期, objectType=article, longId=3642, objectId=911c3642d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=911c3642d8, replyNumber=0, likeNumber=56, createdTime=2012-01-08, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=911c3642d8, moduleTitle=NEJM：贝伐单抗提高攻击性乳腺癌患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=911c3642d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476909, encodeId=b04d14e6909d7, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=JCO:贝伐珠单抗+CP未改善黑色素瘤预后, objectType=article, longId=3553, objectId=f145355379, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f145355379, replyNumber=0, likeNumber=81, createdTime=2011-12-24, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f145355379, moduleTitle=JCO:贝伐珠单抗+CP未改善黑色素瘤预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f145355379)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476908, encodeId=10c614e6908f2, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=FDA取消安维汀（贝伐珠单抗）治疗乳腺癌的适应证, objectType=article, longId=3357, objectId=1026335e60, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1026335e60, replyNumber=0, likeNumber=56, createdTime=2011-11-30, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1026335e60, moduleTitle=FDA取消安维汀（贝伐珠单抗）治疗乳腺癌的适应证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1026335e60)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476907, encodeId=5e2e14e690794, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=贝伐珠单抗与转移性结直肠癌患者ATE有关, objectType=article, longId=3001, objectId=9de93001d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9de93001d5, replyNumber=0, likeNumber=88, createdTime=2011-08-19, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9de93001d5, moduleTitle=贝伐珠单抗与转移性结直肠癌患者ATE有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9de93001d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476906, encodeId=a94614e690627, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=贝伐珠单抗缓解难治性卵巢颗粒细胞瘤患者的症状, objectType=article, longId=2656, objectId=d5f726569d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5f726569d, replyNumber=0, likeNumber=76, createdTime=2011-06-09, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5f726569d, moduleTitle=贝伐珠单抗缓解难治性卵巢颗粒细胞瘤患者的症状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5f726569d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1476905, encodeId=683f14e69059f, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, objectTitle=贝伐单抗能增加癌症患者的重症蛋白尿风险, objectType=article, longId=2637, objectId=54c1263ef0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54c1263ef0, replyNumber=0, likeNumber=93, createdTime=2011-06-09, rootId=0, userName=sunrural_42825359, userId=ef557344179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54c1263ef0, moduleTitle=贝伐单抗能增加癌症患者的重症蛋白尿风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54c1263ef0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

贝伐

2020-05-29

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

NEJM：新辅助化疗和贝伐单抗治疗HER2-阴性乳腺癌

2012-02-05

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

NEJM：新辅助化疗加贝伐单抗治疗乳腺癌

2012-02-05

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

NEJM：贝伐单抗提高攻击性乳腺癌患者生存期

2012-01-08

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

JCO:贝伐珠单抗+CP未改善黑色素瘤预后

2011-12-24

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

FDA取消安维汀（贝伐珠单抗）治疗乳腺癌的适应证

2011-11-30

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

贝伐珠单抗与转移性结直肠癌患者ATE有关

2011-08-19

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

贝伐珠单抗缓解难治性卵巢颗粒细胞瘤患者的症状

2011-06-09

sunrural_42825359 (审核中...)

前往app查看评论内容

#贝伐#

贝伐单抗能增加癌症患者的重症蛋白尿风险

2011-06-09

科室
- - 订阅+
  - 更多科室
工具
服务